Ordering Recommendation
Optimize drug therapy and monitor patient adherence.
Mnemonic
Methodology
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed
Tue, Fri
Reported
1-5 days
New York DOH Approval Status
Specimen Required
Timing of specimen collection: Pre-dose (trough) draw - At steady state concentration.
Gray (Potassium Oxalate/Sodium Fluoride). Also acceptable: Plain Red, Green (Sodium Heparin), Lavender (K2 or K3EDTA) or pink (K2EDTA).
Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 2 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 1 mL)
Refrigerated.
Gel separator tubes. Plasma or whole blood collected in light blue (sodium citrate). Hemolyzed specimens.
After separation from cells: Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 3 years (Avoid repeated freeze/thaw cycles)
Reference Interval
Effective November 16, 2015
Dose-Related Range: | Prazepam (Dose: 20-60 mg/d) (Assayed as Nordiazepam) |
Nordiazepam: | 100-1500 ng/mL |
Toxic: | Greater than 2500 ng/mL |
Interpretive Data
Prazepam is not detected in serum due to its rapid metabolism to nordiazepam. Adverse effects may include dizziness, fatigue, drowsiness, ataxia and weakness.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
Note
Hotline History
CPT Codes
80346 (Alt code: G0480)
Components
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
0090672 | Prazepam (Assay As Nordiazepam) | 3977-6 |
Aliases
- Centrax
- centrax blood level
- prazepam blood level
- Verstran